CSL (company)
| CSL Limited
|
|
|---|---|
_logo.svg){kind=logo} |
|
| legal form | Corporation |
| ISIN | AU000000CSL8 |
| founding | 1994 |
| Seat |
Melbourne , Australia
|
| management | Paul Perreault (CEO) |
| Number of employees | 22,000 |
| sales | 7.92 billion USD (FY 2017/18) |
| Branch | pharmacy |
| Website | www.csl.com.au |
| As of June 30, 2018 | |
CSL Limited is an Australian pharmaceutical company based in Melbourne .
history
CSL (Commonwealth Serum Laboratories) was founded in 1916 as an Australian state company for the manufacture of vaccines . In 1952 the production of blood plasma began . In 1994 the company was privatized and has been trading as CSL Limited ever since. In 2000 the Swiss company ZLB Bioplasma AG was taken over, in 2004 the German company Aventis Behring, which goes back to Emil Adolf von Behring .
activities
The activities of CSL are divided into two areas:
- Under CSL Behring the activities of the production of plasma products and pharmaceuticals are summarized, this includes the acquired companies ZLB Bioplasma and Aventis Behring, which are managed as CSL Behring AG (Switzerland) and CSL Behring GmbH (Germany) today.
- Seqirus is mainly engaged in vaccines - including against influenza - and immune serum
In 2007, CSL Behring was by far the most important division with sales of AUD 2.6 billion - almost 80% of total sales.
share
CSL Limited is listed on the Australian Stock Exchange and is part of the S & P / ASX 50 index, which comprises the 50 largest companies listed on the Australian Stock Exchange. The largest shareholders are HSBC with a good 35 and JP Morgan with around 16%.
See also
- ↑ CSL: website (section Management Board)
- ↑ a b c Annual Report 2018. (PDF) In: www.csl.com. Retrieved September 17, 2019 .
- ↑ CSL: history of the company
- ↑ CSL: Divisions of the company